TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03374098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visitiation
Description: The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~* Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~* Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~* Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~* Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~* Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~* Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo
Study: NCT04203862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of low dose NPC-22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of low/middle dose NPC-22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of middle dose NPC-22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of middle/high dose NPC-22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of high dose NPC-22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22 Placebo
Description: Single administration of NPC-22 Placebo
Study: NCT01810016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Protein Vaccine
Description: NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide
Description: NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Description: NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
Study: NCT02624466

Intervention type: OTHER
Intervention: CKD progress
Description: CKD progress

Intervention type: OTHER
Intervention: CKD progress
Description: CKD progress

Intervention type: OTHER
Intervention: CKD progress
Description: CKD progress
Study: NCT02626286

Intervention type: OTHER
Group type: OTHER
Intervention: HIV quarterly global care
Study: NCT01572922

Intervention type: DEVICE
Group type: OTHER
Intervention: R2*-UTE
Description: Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.

Intervention type: DEVICE
Group type: OTHER
Intervention: R2*-GRE
Description: Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver biopsy
Description: Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
Study: NCT02482766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant alfa, 200 mg/kg
Description: Endotracheal Surfactant administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa, 200 mg/kg
Description: Endotracheal Surfactant administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator for High-frequency Oscillatory Ventilation (HFOV)
Description: This device will be used to perform an HFOV recruitment maneuver before surfactant administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (nCPAP)
Description: After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (nCPAP)
Description: After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
Study: NCT03050151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector Device
Description: Delivery of Dupilumab by auto-injector device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector Device
Description: Delivery of Dupilumab by auto-injector device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe
Description: Delivery of Dupilumab by prefilled syringe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe
Description: Delivery of Dupilumab by prefilled syringe
Study: NCT01116518

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acromioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acromioplasty and rotator cuff reconstruction
Study: NCT04280965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Atypical antipsychotic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care meducations
Description: SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine
Study: NCT04273698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-infant psychotherapy
Description: Brief psychoanalytic parent-infant psychotherapy
Study: NCT03235440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kids N Fitness Program
Description: Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
Study: NCT03427333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Rook® Epicardial Access Kit
Description: Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
Study: NCT03222531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: Drug: sofobuvir/velpatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: Drug: sofobuvir/velpatasvir
Study: NCT03672578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attribution
Description: label with attribution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attribution
Description: label with attribution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attribution
Description: label with attribution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attribution
Description: label with attribution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no attribution
Description: label with no attribution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no attribution
Description: label with no attribution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no attribution
Description: label with no attribution
Study: NCT02868970

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B
Description: Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High-Dose TIV
Description: Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tdap (tetanus-diphtheria-acellular pertussis)
Description: Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal ACWY
Description: Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Herpes Zoster
Description: Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)
Description: Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
Study: NCT06736197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group TVB
Description: Patients who could not reach ETO2 value 90 with tidal volume breathing for 3 min were included in Group TVB tidal volume breathing was continued for 2 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group PSV
Description: Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group PSV
Description: Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group PSV+PEEP
Description: At the 4th minute, preoxygenation was continued by adding 4 cmH2O positive end-expiratory pressure to the same 6 cmH2O pressure support for 1 min in patients whose end-tidal O2 value still reached 90% and who were included in this group.
Study: NCT02296450

Intervention type: BEHAVIORAL
Intervention: Quality of Life (QoL) Assessment
Description: Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
Study: NCT03470675

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural saline + IV saline
Description: Sterile saline injection in the epidural catheter and in the intravenous catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural morphine 3 mg + IV saline
Description: Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural morphine 3 mg + IV ketamine 0.3 mg/kg
Description: Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
Study: NCT03570333

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: progenitor potential of Gingival Mesenchymal cells
Description: tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: progenitor potential of Gingival Mesenchymal cells
Description: tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
Study: NCT04694508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headphones (Disok, Alicante, España)
Description: A pair of non-reusable headphones (Disok, Alicante, Spain)
Study: NCT02593669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation
Description: The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation
Description: The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone and general anesthesia
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone and general anesthesia
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viscoelastic materials
Description: viscoelastic materials are used to protect corneal endothelial cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viscoelastic materials
Description: viscoelastic materials are used to protect corneal endothelial cells.
Study: NCT01103245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 150 mg (ALI 150)
Description: Aliskiren 150mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 150 mg (ALI 150)
Description: Aliskiren 150mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 150 mg (ALI 150)
Description: Aliskiren 150mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone (SPL 25)
Description: spironolactone 25mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone (SPL 25)
Description: spironolactone 25mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone (SPL 25)
Description: spironolactone 25mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 300 mg (ALI 300)
Description: Aliskiren 300mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone 50 mg (SPL 50)
Description: Spironolactone 50 mg daily
Study: NCT02827305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gotukola
Description: 10 ml of mouthwash to be rinsed for duration of 60 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gotukola
Description: 10 ml of mouthwash to be rinsed for duration of 60 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling
Description: Ultrasonic scaling was performed in one visit on both upper and lower arches.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling
Description: Ultrasonic scaling was performed in one visit on both upper and lower arches.
Study: NCT00177138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Starting POD #1 0.06 mg/kg/day in 2 divided doses;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)
Study: NCT01121978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Description: Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
Study: NCT02198612

Intervention type: OTHER
Group type: OTHER
Intervention: Manual puncture point compression
Description: Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
Study: NCT01557023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: barrier methods

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: barrier methods
Study: NCT01306890

Intervention type: BIOLOGICAL
Intervention: sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
Study: NCT03878004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamTBvac vaccine
Description: introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: introduction of placebo twice into a shoulder with an 8-week interval.